Brief: BioXcel Therapeutics Q1 Basic EPS USD -0.87 Vs. IBES Estimate USD -0.7
09/05/2024 12:00
May 09 (Reuters) - BioXcel Therapeutics Q1 net income USD -26.791 million vs. IBES estimate USD -23.2 million. * Q1 operating income USD -24.163 million vs. IBES estimate USD -20.3 million * Q1 operating expenses USD 24.745 million * Q1 revenue USD 582 thousand vs. IBES estimate USD 464 thousand
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty